Over two days this week, an FDA advisory committee worked through seven peptides and decided which ones it thinks compounding pharmacies should be allowed to make. Six got a yes. One got a no. The FDA’s own scientists had argued against all seven.
We covered each day as it happened. This is the whole thing in one place: what the committee actually is, how every vote landed, and the part that matters most, which is that none of it changes what is legal today.
What this committee is, and what it was voting on
The panel is the Pharmacy Compounding Advisory Committee, or PCAC. It advises the FDA on which raw ingredients compounding pharmacies are permitted to work with. The specific question this week was whether seven peptides should be added to the Section 503A Bulk Drug Substances List.
That list is the whole ballgame. A substance on it can be compounded by a licensed pharmacy for an individual patient without the ingredient itself having gone through full FDA drug approval. Off the list, a compounding pharmacy legally cannot make it. In 2023 the FDA moved several of these peptides into a category that effectively pulled them off the table, which is why access has been complicated since.
So this was not a vote on whether peptides work. It was a narrower regulatory question: can these specific compounds be made to a consistent enough standard for a pharmacy to compound them safely, for the specific uses proposed.
The full scorecard
Here is how all seven landed across both days.
| Peptide | Proposed use | Vote | Result |
|---|---|---|---|
| BPC-157 | Ulcerative colitis | 8 to 6, 1 abstention | Recommended |
| KPV | Inflammation | 8 to 6, 1 abstention | Recommended |
| TB-500 | Wound healing | Majority in favor | Recommended |
| MOTS-c | Obesity, osteoporosis | Majority in favor | Recommended |
| Semax | Migraines, cerebral ischemia, trigeminal neuralgia | 8 to 5 | Recommended |
| Epitalon | Insomnia | 7 to 4 | Recommended |
| Emideltide (DSIP) | Opioid withdrawal, chronic insomnia, narcolepsy | 6 to 7 | Rejected |
BPC-157 and KPV each got two separate votes to account for different chemical forms of the molecule. Note the margins throughout. Nothing here was lopsided. Even the peptides that passed did so with a real bloc of members voting no.
The pattern is more interesting than the headline
The easy story is “FDA panel backs peptides.” That is technically true and mostly misses the point.
What actually happened is a committee that took each peptide on its own terms. Thursday’s four all passed, but never by more than a couple of votes. Friday, when they got to emideltide, they stopped. Its proposed uses include opioid withdrawal and narcolepsy, conditions where getting it wrong carries real consequences, and one panel member, pharmacy officer David Pope, broke from the group over what he called potentially dangerous downstream consequences.
A committee that rejects one out of seven, on close votes, weighing risk by indication, is not rubber-stamping anything. That distinction should matter to you more than the raw tally, because it tells you the yes votes were not automatic.
The part almost every headline skipped
Going into both days, the FDA’s own staff recommended against all seven peptides. Not the one that failed. All of them, including the six the committee went on to endorse.
Their objection was not really about whether these compounds do anything. It was about identity and consistency. Russell Wesdyk from the FDA made the point on day one: you will see many different forms of these peptides all sold under the same name, which makes it nearly impossible to write a manufacturing standard for what a pharmacy is actually compounding. On day two, Mary Thanh Hai, who directs the FDA’s Office of New Drugs, made the flip side of it about the current market. In the grey market, she said, testing is not a requirement to be sent to us. The agency cannot vouch for what it never sees.
You do not have to agree with the FDA’s conclusion to take that concern seriously. It is the most useful thing to come out of the whole meeting, and it applies no matter how the votes went.
What happens next, and how long it takes
This is where the excitement online gets ahead of reality.
A PCAC recommendation is advice. The FDA decides, and it is not bound by the panel, which matters more than usual here because the agency’s own staff took the opposite position on every single peptide. That is an unusual split.
Even in the best case for access, a peptide does not become compoundable because a committee said yes. Adding a substance to the 503A list requires formal notice-and-comment rulemaking: the FDA publishes a proposed rule, opens a public comment period, reviews the comments, and issues a final rule. That process runs a year or more, not weeks. And it can end in no for a peptide the committee said yes to.
So the honest bottom line is the same as it was on Wednesday, before any of this: what a compounding pharmacy can legally make has not changed. If someone tries to sell you a peptide right now on the strength of these votes, they are selling ahead of the rules.
What it means for patients
Our approach did not move this week, and I would be wary of any clinic whose approach did.
The thing worth taking from these two days is the same thing the FDA kept circling from its side of the argument: what matters is knowing exactly what is in the vial. Every peptide we use carries a batch-specific certificate of analysis from an independent laboratory, covering identity and purity by HPLC, endotoxin testing to USP standards, heavy metals, and sterility. That is paired with the clinical parts that actually determine whether peptide therapy is a good idea for a given person: baseline labs where indicated, a protocol with a defined start and stop rather than an open-ended prescription, and follow-up to judge honestly whether it is doing anything.
That is how we handle the peptides in this week’s news, from BPC-157 and MOTS-c to semax and combination protocols like the BPC-157 and TB-500 stack.
The clearest takeaway, if you want one, is about sourcing. A committee just spent two days debating whether these compounds can be manufactured to a reliable standard at all. A vial from an anonymous online seller sits entirely outside that conversation, with no testing and no documentation to check. The risk in peptides is rarely the peptide. It is not knowing what you actually have.
Where this goes from here
My read, as someone who practices emergency medicine and also runs a wellness practice: this week was directionally good for patient access and a fair reminder that the evidence base is thinner than the marketing. Both are true at once. A peptide can be worth trying under supervision and still be under-studied, and most of the disagreement in that room was about which of those facts should carry more weight.
What would actually settle it is real trials. Until then, the responsible version of this is supervised use, verified sourcing, clear expectations, and a willingness to stop something that is not working. That does not change based on a vote, and it will not change when the FDA issues whatever it issues a year from now.
Have questions about peptide therapy, or want an honest review of something you are already taking? Call us at (727) 274-1972 or book online at olympiaaesthetics.com/contact/. You can read our day-by-day coverage of the votes here: day one and day two. More on our peptide therapy programs is here.
This post covers a regulatory development and is general information, not medical advice. Peptide therapy is not appropriate for everyone. Individual candidacy is determined during a medical consultation.
